Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 173

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Jackie Tileston: Nondual Mysticism, 5-MeO-DMT, and the Trouble with Psychedelic Art

FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending

Weekly Psychedelic Policy Briefing: Oct. 27, 2026

Pharma Moves In: Investors, Developers and Lilly’s Carole Ho at the Psychedelic Healthcare Forum

Mostly Supportive, Somewhat Divided: Stakeholders Respond to FDA’s Psychedelics Docket

atai Life Sciences to Participate in September Investor Events

Mindset Pharma Files National Patents Protecting Family 1 Application in 16...

Optimi Health Signs First International Mushroom Supply Agreement with UK-based Avida...

BetterLife and Collaborators to Submit Key Joint Research Publication

MindMed to Participate in H.C. Wainwright Global Investment ConferenceUSA – EnglishUSA...

PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX™...

PsyBio Therapeutics to Present at Upcoming Investor Events in September 2022

PT353 – Dr. James Fadiman, Dr. Sam Gandy, & Dr. David...

Psychedelic Bulletin #117 – A Deep Dive Into Psilocybin for Alochol...

Psychedelic Research Bulletin: July and August 2022

Load more

EDITOR PICKS

Jackie Tileston: Nondual Mysticism, 5-MeO-DMT, and the Trouble with Psychedelic Art

FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban...

Weekly Psychedelic Policy Briefing: Oct. 27, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©